Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir

Abstract excerpt

The U.S. FDA approval of PAXLOVID, a combination therapy of nirmatrelvir and ritonavir has significantly boosted our morale in fighting the COVID-19 pandemic. Nirmatrelvir is an inhibitor of the main protease (M Pro ) of SARS-CoV-2. Since many SARS-CoV-2 variants that resist vaccines and antibodies have emerged, a concern of acquired viral resistance to nirmatrelvir naturally arises. Here, possible mutations in M...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Computational Drug Discovery Methods
• Share to SARS-CoV-2 and COVID-19 Research
• Share to vaccines and immunoinformatics approaches